This article was originally published in The Gray Sheet
Shareholders file for temporary injunction in New York federal court June 2 against a forced re-integration of the unit with parent firm Genzyme Corp. via a stock swap proposed May 8. Genzyme Corp. holds that the elimination of the separate tracking stocks for Genzyme Biosurgery and Genzyme Molecular Oncology is consistent with provisions of its corporate charter. Biosurgery shareholders allege that Genzyme Corp. delayed release of certain information that would have translated into a higher sale price, including plans to sell Biosurgery's cardiothoracic unit, in order to get a business worth "at least $1.5-$2 bil. for a mere $72 mil." in stock. The re-integration is slated for June 30 (1"The Gray Sheet" May 19, 2003, p. 21)...
You may also be interested in...
Genzyme Biosurgery plans to divest the bulk of its cardiothoracic devices business by year-end to focus on its orthopedics and biosurgical specialties units
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Among the largest gaps in safety data is non-clinical research on CBD use's effect on developing fetus and adolescent brain, in utero/lactational exposure, reproductive toxicity and the potential for a latency period before toxicity, says FDA neuroscientist Andrew Shen.